Cargando…
Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy
Enterotoxigenic E. coli (ETEC) and Shigella are enteropathogens causing significant global morbidity and mortality, particularly in low-income countries. No licensed vaccine exists for either pathogen, but candidates are in development, with the most advanced candidates potentially approaching pivot...
Autores principales: | Hosangadi, Divya, Smith, Peter G., Giersing, Birgitte K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892262/ https://www.ncbi.nlm.nih.gov/pubmed/29031690 http://dx.doi.org/10.1016/j.vaccine.2017.09.083 |
Ejemplares similares
-
Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC
por: Harutyunyan, Shushan, et al.
Publicado: (2020) -
Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus
por: Das, Jai K, et al.
Publicado: (2013) -
What Drives the Value of a Shigella Vaccine?
por: Hausdorff, William P., et al.
Publicado: (2022) -
Pivotal Shigella Vaccine Efficacy Trials—Study Design Considerations from a Shigella Vaccine Trial Design Working Group
por: Pavlinac, Patricia B., et al.
Publicado: (2022) -
Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial
por: Girardi, Petra, et al.
Publicado: (2022)